Loading…
Annexin A2: The diversity of pathological effects in tumorigenesis and immune response
Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmi...
Saved in:
Published in: | International journal of cancer 2022-08, Vol.151 (4), p.497-509 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623 |
---|---|
cites | cdi_FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623 |
container_end_page | 509 |
container_issue | 4 |
container_start_page | 497 |
container_title | International journal of cancer |
container_volume | 151 |
creator | Huang, Yanjie Jia, Mengzhen Yang, Xiaoqing Han, Hongyan Hou, Gailing Bi, Liangliang Yang, Yueli Zhang, Ruoqi Zhao, Xueru Peng, Chaoqun Ouyang, Xinshou |
description | Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmin, which participates in pathophysiologic processes such as tumor cell invasion and metastasis, bleeding diseases, angiogenesis, inducing the expression of inflammatory factors. In addition, the ANXA2 on the cell membrane mediates immune response via its interaction with surface proteins of pathogens, C1q, toll‐like receptor 2, anti‐dsDNA antibodies and immunoglobulins. Nuclear ANXA2 plays a role as part of a primer recognition protein complex that enhances DNA synthesis and cells proliferation by acting on the G1‐S phase of the cell. ANXA2 reduction leads to the inhibition of invasion and metastasis in multiple tumor cells, bleeding complications in acute promyelocytic leukemia, retinal angiogenesis, autoimmunity response and tumor drug resistance. In this review, we provide an update on the pathological effects of ANXA2 in both tumorigenesis and the immune response. We highlight ANXA2 as a critical protein in numerous malignancies and the immune host response. |
doi_str_mv | 10.1002/ijc.34048 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2656202036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2676562217</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623</originalsourceid><addsrcrecordid>eNp10E9PwjAcxvHGaATRg2_ANPGih0HbtdvwRoh_MCReiNdltL9BydZiu6m8e4tDDyaeeugnT9ovQpeUDCkhbKQ3chhzwrMj1KdknEaEUXGM-uGORCmNkx46835DCKWC8FPUiwVPOaOsj14nxsCnNnjC7vBiDVjpd3BeNztsS7wtmrWt7ErLosJQliAbjwNu2to6vQIDXntcGIV1XbcGsAO_tcbDOTopi8rDxeEcoMXD_WL6FM1fHmfTyTySXPAsoimVKbAkFSJZxhlwteTJkkkKStBMMkWUYCphmYKSZUQVKnxJCDEWrBQJiwfoppvdOvvWgm_yWnsJVVUYsK3PWRJUiBAngV7_oRvbOhMeF1S6d4ymQd12SjrrvYMy3zpdF26XU5LvW-ehdf7dOtirw2K7rEH9yp-4AYw68KEr2P2_lM-ep93kF7jFhp4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676562217</pqid></control><display><type>article</type><title>Annexin A2: The diversity of pathological effects in tumorigenesis and immune response</title><source>Wiley</source><creator>Huang, Yanjie ; Jia, Mengzhen ; Yang, Xiaoqing ; Han, Hongyan ; Hou, Gailing ; Bi, Liangliang ; Yang, Yueli ; Zhang, Ruoqi ; Zhao, Xueru ; Peng, Chaoqun ; Ouyang, Xinshou</creator><creatorcontrib>Huang, Yanjie ; Jia, Mengzhen ; Yang, Xiaoqing ; Han, Hongyan ; Hou, Gailing ; Bi, Liangliang ; Yang, Yueli ; Zhang, Ruoqi ; Zhao, Xueru ; Peng, Chaoqun ; Ouyang, Xinshou</creatorcontrib><description>Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmin, which participates in pathophysiologic processes such as tumor cell invasion and metastasis, bleeding diseases, angiogenesis, inducing the expression of inflammatory factors. In addition, the ANXA2 on the cell membrane mediates immune response via its interaction with surface proteins of pathogens, C1q, toll‐like receptor 2, anti‐dsDNA antibodies and immunoglobulins. Nuclear ANXA2 plays a role as part of a primer recognition protein complex that enhances DNA synthesis and cells proliferation by acting on the G1‐S phase of the cell. ANXA2 reduction leads to the inhibition of invasion and metastasis in multiple tumor cells, bleeding complications in acute promyelocytic leukemia, retinal angiogenesis, autoimmunity response and tumor drug resistance. In this review, we provide an update on the pathological effects of ANXA2 in both tumorigenesis and the immune response. We highlight ANXA2 as a critical protein in numerous malignancies and the immune host response.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.34048</identifier><identifier>PMID: 35474212</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Acute promyeloid leukemia ; Angiogenesis ; anti‐ANXA2 antibodies ; ANXA2 function ; ANXA2 heterotetramer ; ANXA2 monomers ; Autoimmunity ; Bleeding ; Cancer ; Cell membranes ; Cell proliferation ; Degeneration ; DNA biosynthesis ; Drug resistance ; Immune response ; Immunoglobulins ; Inflammation ; Medical research ; Mesenchyme ; Metastases ; Metastasis ; phosphorylated ANXA2 ; Plasmin ; Promyeloid leukemia ; S phase ; Tumor cells ; Tumorigenesis</subject><ispartof>International journal of cancer, 2022-08, Vol.151 (4), p.497-509</ispartof><rights>2022 UICC.</rights><rights>2022 UICC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623</citedby><cites>FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623</cites><orcidid>0000-0001-5035-4411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35474212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yanjie</creatorcontrib><creatorcontrib>Jia, Mengzhen</creatorcontrib><creatorcontrib>Yang, Xiaoqing</creatorcontrib><creatorcontrib>Han, Hongyan</creatorcontrib><creatorcontrib>Hou, Gailing</creatorcontrib><creatorcontrib>Bi, Liangliang</creatorcontrib><creatorcontrib>Yang, Yueli</creatorcontrib><creatorcontrib>Zhang, Ruoqi</creatorcontrib><creatorcontrib>Zhao, Xueru</creatorcontrib><creatorcontrib>Peng, Chaoqun</creatorcontrib><creatorcontrib>Ouyang, Xinshou</creatorcontrib><title>Annexin A2: The diversity of pathological effects in tumorigenesis and immune response</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmin, which participates in pathophysiologic processes such as tumor cell invasion and metastasis, bleeding diseases, angiogenesis, inducing the expression of inflammatory factors. In addition, the ANXA2 on the cell membrane mediates immune response via its interaction with surface proteins of pathogens, C1q, toll‐like receptor 2, anti‐dsDNA antibodies and immunoglobulins. Nuclear ANXA2 plays a role as part of a primer recognition protein complex that enhances DNA synthesis and cells proliferation by acting on the G1‐S phase of the cell. ANXA2 reduction leads to the inhibition of invasion and metastasis in multiple tumor cells, bleeding complications in acute promyelocytic leukemia, retinal angiogenesis, autoimmunity response and tumor drug resistance. In this review, we provide an update on the pathological effects of ANXA2 in both tumorigenesis and the immune response. We highlight ANXA2 as a critical protein in numerous malignancies and the immune host response.</description><subject>Acute promyeloid leukemia</subject><subject>Angiogenesis</subject><subject>anti‐ANXA2 antibodies</subject><subject>ANXA2 function</subject><subject>ANXA2 heterotetramer</subject><subject>ANXA2 monomers</subject><subject>Autoimmunity</subject><subject>Bleeding</subject><subject>Cancer</subject><subject>Cell membranes</subject><subject>Cell proliferation</subject><subject>Degeneration</subject><subject>DNA biosynthesis</subject><subject>Drug resistance</subject><subject>Immune response</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>Medical research</subject><subject>Mesenchyme</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>phosphorylated ANXA2</subject><subject>Plasmin</subject><subject>Promyeloid leukemia</subject><subject>S phase</subject><subject>Tumor cells</subject><subject>Tumorigenesis</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp10E9PwjAcxvHGaATRg2_ANPGih0HbtdvwRoh_MCReiNdltL9BydZiu6m8e4tDDyaeeugnT9ovQpeUDCkhbKQ3chhzwrMj1KdknEaEUXGM-uGORCmNkx46835DCKWC8FPUiwVPOaOsj14nxsCnNnjC7vBiDVjpd3BeNztsS7wtmrWt7ErLosJQliAbjwNu2to6vQIDXntcGIV1XbcGsAO_tcbDOTopi8rDxeEcoMXD_WL6FM1fHmfTyTySXPAsoimVKbAkFSJZxhlwteTJkkkKStBMMkWUYCphmYKSZUQVKnxJCDEWrBQJiwfoppvdOvvWgm_yWnsJVVUYsK3PWRJUiBAngV7_oRvbOhMeF1S6d4ymQd12SjrrvYMy3zpdF26XU5LvW-ehdf7dOtirw2K7rEH9yp-4AYw68KEr2P2_lM-ep93kF7jFhp4</recordid><startdate>20220815</startdate><enddate>20220815</enddate><creator>Huang, Yanjie</creator><creator>Jia, Mengzhen</creator><creator>Yang, Xiaoqing</creator><creator>Han, Hongyan</creator><creator>Hou, Gailing</creator><creator>Bi, Liangliang</creator><creator>Yang, Yueli</creator><creator>Zhang, Ruoqi</creator><creator>Zhao, Xueru</creator><creator>Peng, Chaoqun</creator><creator>Ouyang, Xinshou</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5035-4411</orcidid></search><sort><creationdate>20220815</creationdate><title>Annexin A2: The diversity of pathological effects in tumorigenesis and immune response</title><author>Huang, Yanjie ; Jia, Mengzhen ; Yang, Xiaoqing ; Han, Hongyan ; Hou, Gailing ; Bi, Liangliang ; Yang, Yueli ; Zhang, Ruoqi ; Zhao, Xueru ; Peng, Chaoqun ; Ouyang, Xinshou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acute promyeloid leukemia</topic><topic>Angiogenesis</topic><topic>anti‐ANXA2 antibodies</topic><topic>ANXA2 function</topic><topic>ANXA2 heterotetramer</topic><topic>ANXA2 monomers</topic><topic>Autoimmunity</topic><topic>Bleeding</topic><topic>Cancer</topic><topic>Cell membranes</topic><topic>Cell proliferation</topic><topic>Degeneration</topic><topic>DNA biosynthesis</topic><topic>Drug resistance</topic><topic>Immune response</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>Medical research</topic><topic>Mesenchyme</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>phosphorylated ANXA2</topic><topic>Plasmin</topic><topic>Promyeloid leukemia</topic><topic>S phase</topic><topic>Tumor cells</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yanjie</creatorcontrib><creatorcontrib>Jia, Mengzhen</creatorcontrib><creatorcontrib>Yang, Xiaoqing</creatorcontrib><creatorcontrib>Han, Hongyan</creatorcontrib><creatorcontrib>Hou, Gailing</creatorcontrib><creatorcontrib>Bi, Liangliang</creatorcontrib><creatorcontrib>Yang, Yueli</creatorcontrib><creatorcontrib>Zhang, Ruoqi</creatorcontrib><creatorcontrib>Zhao, Xueru</creatorcontrib><creatorcontrib>Peng, Chaoqun</creatorcontrib><creatorcontrib>Ouyang, Xinshou</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yanjie</au><au>Jia, Mengzhen</au><au>Yang, Xiaoqing</au><au>Han, Hongyan</au><au>Hou, Gailing</au><au>Bi, Liangliang</au><au>Yang, Yueli</au><au>Zhang, Ruoqi</au><au>Zhao, Xueru</au><au>Peng, Chaoqun</au><au>Ouyang, Xinshou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Annexin A2: The diversity of pathological effects in tumorigenesis and immune response</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2022-08-15</date><risdate>2022</risdate><volume>151</volume><issue>4</issue><spage>497</spage><epage>509</epage><pages>497-509</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal transition, which can cause tumorigenesis and accelerate thymus degeneration. The elevated ANXA2 heterotetramer facilitates the production of plasmin, which participates in pathophysiologic processes such as tumor cell invasion and metastasis, bleeding diseases, angiogenesis, inducing the expression of inflammatory factors. In addition, the ANXA2 on the cell membrane mediates immune response via its interaction with surface proteins of pathogens, C1q, toll‐like receptor 2, anti‐dsDNA antibodies and immunoglobulins. Nuclear ANXA2 plays a role as part of a primer recognition protein complex that enhances DNA synthesis and cells proliferation by acting on the G1‐S phase of the cell. ANXA2 reduction leads to the inhibition of invasion and metastasis in multiple tumor cells, bleeding complications in acute promyelocytic leukemia, retinal angiogenesis, autoimmunity response and tumor drug resistance. In this review, we provide an update on the pathological effects of ANXA2 in both tumorigenesis and the immune response. We highlight ANXA2 as a critical protein in numerous malignancies and the immune host response.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>35474212</pmid><doi>10.1002/ijc.34048</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-5035-4411</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0020-7136 |
ispartof | International journal of cancer, 2022-08, Vol.151 (4), p.497-509 |
issn | 0020-7136 1097-0215 |
language | eng |
recordid | cdi_proquest_miscellaneous_2656202036 |
source | Wiley |
subjects | Acute promyeloid leukemia Angiogenesis anti‐ANXA2 antibodies ANXA2 function ANXA2 heterotetramer ANXA2 monomers Autoimmunity Bleeding Cancer Cell membranes Cell proliferation Degeneration DNA biosynthesis Drug resistance Immune response Immunoglobulins Inflammation Medical research Mesenchyme Metastases Metastasis phosphorylated ANXA2 Plasmin Promyeloid leukemia S phase Tumor cells Tumorigenesis |
title | Annexin A2: The diversity of pathological effects in tumorigenesis and immune response |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A57%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Annexin%20A2:%20The%20diversity%20of%20pathological%20effects%20in%20tumorigenesis%20and%20immune%20response&rft.jtitle=International%20journal%20of%20cancer&rft.au=Huang,%20Yanjie&rft.date=2022-08-15&rft.volume=151&rft.issue=4&rft.spage=497&rft.epage=509&rft.pages=497-509&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.34048&rft_dat=%3Cproquest_cross%3E2676562217%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4548-171c7e267556b38e4db46b2c1ed518c2d0d52d628def280dad002555952f5623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2676562217&rft_id=info:pmid/35474212&rfr_iscdi=true |